South Korean medical AI company Vuno has developed a deep learning model that predicts the onset of atrial fibrillation up to a month before it occurs, marking a significant shift from detecting existing arrhythmias to forecasting future cardiac events. The technology analyzes single portable ECG readings to identify patients at imminent risk—even when no abnormal heart rhythm is currently present.

From Detection to Prediction: A New Paradigm in Cardiac Monitoring

The AI model, developed by Vuno in collaboration with researchers from Chonnam National University Hospital and Hallym University Dongtan Sacred Heart Hospital, achieved an area under the receiver operating characteristic curve (AUROC) of 0.787 for 31-day predictions. The system also forecasts atrial fibrillation risk at 7-day (AUROC 0.793) and 14-day (AUROC 0.785) intervals.

According to research published in JMIR Medical Informatics, the model was validated using 386,519 ECG readings from 8,206 users of the HATIV P30 portable ECG device collected between March 2023 and November 2024 in South Korea. The technology addresses a critical diagnostic gap: atrial fibrillation symptoms are often intermittent or absent, leading to delayed diagnosis despite the condition's association with increased stroke and heart failure risk.

Real-World Validation Demonstrates Clinical Utility

In a prospective validation cohort of 144 high-risk patients with no prior atrial fibrillation diagnosis who were followed for 31 days, the AI's predictive accuracy proved clinically significant. All five newly identified atrial fibrillation cases occurred in patients the algorithm classified as high-risk, while zero cases emerged in the low-risk group.

"This predictive capability enables proactive monitoring and early intervention for atrial fibrillation before symptomatic episodes occur," the research team noted. The technology allows clinicians to use portable ECG devices not merely for arrhythmia detection but for risk stratification and targeted follow-up of vulnerable populations.

Joo Sung-hoon, Chief Technology Officer at Vuno, emphasized the model's potential to transform cardiac care for high-risk individuals, particularly elderly and hypertensive patients who can now access continuous risk assessment without requiring symptomatic episodes.

Competitive Positioning in Expanding Remote Monitoring Market

Vuno's predictive approach represents a strategic differentiation in the increasingly crowded portable ECG market, where consumer electronics giants like Apple and Samsung compete alongside established medical device manufacturers. By shifting from detection to prediction, the company creates new clinical utility that may open additional reimbursement pathways for AI-enabled portable monitoring devices.

The development positions Vuno, traded on the Korean stock exchange under ticker 338220.KQ, to compete in the expanding remote patient monitoring market with a technology that addresses the intermittent nature of paroxysmal atrial fibrillation—a longstanding challenge in cardiology that has limited the effectiveness of episodic screening approaches.

For healthcare providers, the technology enables a proactive rather than reactive approach to atrial fibrillation management, potentially reducing stroke risk through earlier diagnosis and treatment initiation in high-risk populations identified through routine portable ECG screening.

Sources

  1. Vuno Develops AI That Predicts Atrial Fibrillation Within a Month — Seoul Economic Daily